Medicamentsen-ligne vous propose les traitements dont vous avez besoin afin de prendre soin de votre santé sexuelle. Avec plus de 6 ans d'expérience et plus de 90.000 clients francophones, nous étions la première clinique fournissant du
acheter levitra original en France à vente en ligne et le premier vendeur en ligne de Kamagra dans le monde. Pourquoi prendre des risques si vous pouvez être sûr avec Medicamentsen-ligne - Le service auquel vous pouvez faire confiance.
Microsoft word - hydrogel5.doc
PREPARATION OF A 5% FLURBIPROFEN HYDROGEL
Ibuprofen, Flurbiprofen, Hydrogel, Dermatology
The administration of drugs via the skin has benefits above oral administration. It is a non-invasive
administration and is suitable for people who cannot use drugs orally (unconscious or vomiting). Also, the
first-pass metabolism and gastro intestinal side effects can be avoided. However, it is difficult to reach
therapeutic levels because of the difficulty for the druf to penetrate the skin barrier. Another disadvantage is
inter-individual differences in penetration of the skin. Also, intra-individual differences do appear, because
of the existence of multiple skin-types on one individual. To administrate drugs through the skin, the drug
itself must comply to certain factors. The drug has to have, among others, a strong potency, must not exceed
a certain molecular size (MW under 500 Dalton) and must not be irritating to the skin. The penetration of
drugs through the skin can be influenced by the compounds in the topical preparation (1,2).
This study looks at the possibilities of the development of a 5% flurbiprofen hydrogel. The formulation of
several commercial ibuprofen hydrogels was used as a starting point. These ibuprofen hydrogels are used
for the treatment of muscle pain, soft tissue rheumatism and sport injuries. The hydrogel formulation is
chosen because several studies with ibuprofen show that the hydrogel reaches higher plasma concentrations
in shorter time than for example cream or unguent. In a study by Seth (3) different topical formulations
(hydrogel, hydrophilic ointment, emulsion cream) of ibuprofen are compared. The parameters used are
Cmax (maximum blood concentration) and Tmax (the time required for appearance of Cmax). This study
shows that hydrogel reaches the highest Cmax with the shortest Tmax. The hydrophilic ointment shows the
longest Tmax and lowest Cmax, the results of the emulsion cream are in between. The explanation given is
that the water/ethanol mixture in the hydrogel increases the penetration and the absorption of ibuprofen
through the skin to a greater extent than the lipophilic phase of the ointment and the emulsion cream. A
study of Treffel (4) also shows higher epidermal concentration by using ibuprofen hydrogels than ibuprofen
emulsions. Dominikus (5) has compared oral administration (tablet) with topical administration (hydrogel)
of ibuprofen. Concentrations of ibuprofen in tissue and blood were examined. It shows that oral
administration resulted in higher concentrations of ibuprofen in e.g. blood plasma and synovial fluid while
topical administration gives higher concentrations in muscle tissue and subcutis.
The objective of this study is to prepare a clear and transparent flurbiprofen hydrogel with good consistency
and cosmetic appearance. Both 5% ibuprofen as well as 5% flurbiprofen hydrogels are made. Of both
substances the differences in solubility and pH behaviour (solubility by different pHs) are examined. MATERIALS & METHODS
Composition Ibuprofen 5% 100 gram
Composition flurbiprofen 5% 100 gram Flurbiprofen
Preparation protocol Weigh all components. Dissolve meglumine (N-Methylglucamine) in approximately 80 grams of water. Subsequently, dissolve the ibuprofen/ flurbiprofen in the solution with meglumine (warming). Correct the pH to 6.8 with HCl (solution has to stay transparent). Weigh Kathon CG (safety protocol). Add Kathon CG to the solution. Put the solution in a tarred mortar. Add hydroxyethylcellulose while mixing firmly. Mix thorough until a smooth hydrogel is formed. Add purified water up to a 100 grams. Explanatory note to the usage of meglumine (N-Methylglucamine) and Kathon CG • To get a clear, transparent hydrogel the ibuprofen/ flurbiprofen has to be dissolved. This can be
obtained by using equimolar quantities of meglumine dissolved in a part of the required water followed by dissolved ibuprofen/ flurbiprofen in the meglumine-solution. The usage of equimolar quantities of NaOH for obtaining a 5%-solution of ibuprofen/ flurbiprofen is not possible in the case of flurbiprofen (see solubility of flurbiprofen).
• Kathon CG is the preservative in the gel. Kathon CG is used in cosmetics. 50 mg correspond with
7.5 ppm; this concentration gives a good preservation and minimal skin irritation (see product information of Kathon CG). By using Kathon CG, the pH is a critical parameter for the conservation; a pH of 8 or higher weakens the conservation qualities, reason to keep the pH as low as possible (about 7; flurbiprofen/ ibuprofen are dissolved at this pH) (see product information of Kathon CG and results of pH-series). The temperature must be kept under 50°C to preserve conservation qualities of Kathon CG. There are special safety protocols operative while using Kathon CG in the preparation of the hydrogel because of it's corrosive nature(see product information of Kathon CG).
The solubility of ibuprofen/ flurbiprofen with equimolar quantities of meglumine is determent for different
pHs. This is done to examine at which pH the components are dissolved (the lower pH the better for the
conserving activity of Kathon CG). The used pH-buffersolutions are made according to the study of
Herzfeldt and Kümmel (1983) to the dissociation constants and solubility’s of NSAIDs.
Buffer solutions (Herzfeldt and Kümmel) (6)
The different pHs are made by using different combinations of buffer A and B (pH-curve buffer solutions).
• Ibuprofen with equimolar quantities of NaOH dissolves in water while heating (5% solution is
obtainable). The pH of the solution is 7.8.
• With equimolar quantities of NaOH a 5% solution of flurbiprofen is obtainable while heating up to 50
• The solubility of flurbiprofen(sodium) is qualitatively determined at two pH-values: Flurbiprofen
• With equimolar quantities of meglumine dissolved in water a 5% solution of ibuprofen or flurbiprofen is
obtained while heating. After cooling a transparent solution remains. The pH of the ibuprofen/meglumine-solution is 7.8. The pH of the flurbiprofen/meglumine-solution is 7.7. The pH of both solutions is lowered to 6.8 using HCL.
• With equimolar quantities of trometamol dissolved in water a 5% solution of ibuprofen or flurbiprofen
is obtainable while heating. But during cooling it becomes cloudy. The pH of this solution is 7.1. Lowering or raising the pH of the trometamol/flurbiprofen-solution does not deliver a transparant solution.
1 Equimolar quantity (example):
M(NaOH)/M(ibuprofen)* x grams ibuprofen = x grams NaOH
Legenda: Molecular weight
Taking the above mentioned results into account the preparation of Ibuprofen and Flurbiprofen gels is as
Composition Ibuprofen hydrogel 5% 100 gram
Composition Flurbiprofen hydrogel 5% 100 gram Flurbiprofen
Meglumine is essential to obtain a clear and transparent 5% flurbiprofen hydrogel. The optimal pH is
established at 6.8. At this pH the flurbiprofen is still soluble and the conservative capacity of Kathon CG
is preserved. The consistency is still a problem. At 1.8% hydroxyethylcellulose it is median and the
cosmetic appearance is good. At 2% the consistency is good but the cosmetic value becomes less. With
dermal application of the clear, transparent 2%- gel it becomes cloudy and sticky, while using the 1.8%-gel
this does not happen and the gel soaks into the skin.
Clotting during preparation of the 2% hydrogel by hand can be overcome by use of a rotor-statormixer.
A clear transparant 1.8 - 2% hydrogel with either 5%Ibuprofen or Flurbiprofen can be developed. The in
vitro-release of flurbiprofen from the hydrogel as also the bioadhesive characteristics (7,8) will be subject
of further research. REFERENCES
1.- Finnin B.C., Morgan T.M. Transdermal penetration enhancers: applications, limitations and potential.
J Pharm Sci
; 1999: 88(10): 955-958
2.- Okuyama H., Ikeda Y., Kasai S., Imamori K., Takayama K., Nagai T. Influence of non-ionic surfactants,
pH and propylene glycol on percutaneous absorption of piroxicam from cataplasm. International Journal of Pharmaceutics
; 1999: 186: 141-148
3.- Seth P.L. Percutaneous absorption of ibuprofen from different formulations; Comparative study with
gel,hydrophilic ointment and emulsion cream. Drug Res.
; 1993: 43(II): 919-921
4.- Treffel P., Gabard B. Ibuprofen epidermal levels after topical application in vitro: effect of formulation,
application time, dose variation and occlusion. British Journal of Dermatology
; 1993: 129: 286-291
5.- Dominikus M., Nicolakis M., Kotz R., Wilkinson F.E., Kaiser R.R., Chlud K.
Comparison of tissue and plasma levels of ibuprofen after oral and topical administration. Drug Res.
; 1996: 46(II): 1138-1143
6.- Herzfeldt C.D., Kümmel R. Dissociation constants, solubilities and dissolution rates of
some selected nonsteroidal antiinflammatories. Drug Development and Industrial Pharmacy
; 1983: 9(5): 767-793
7.- Jones D.S., Irwin C.R., Woolfson A.D., Djokic J., Adams V.
Physicochemical characterisation and preliminary in vivo efficacy of bioadhesive, semisolid formulations containing flurbiprofen for treatment of gingivitis. J Pharm Sci
; 1999: 88(6): 592-598
8.- Zaman M., McAllister M., Martini L.G., Lawrence M.J.
The physico-chemical and biological factors influencing bioadhesion. Biopharm Europe
, 1999: Sept.: 52-60
A14 Reagan Koczubic A13 Mitchell Young A12 Emily Brodie A11 Emily Hackett A10 William Wallace A9 Alex Young A8 A2 Jaymee-Lyn Inglis Items discussed Welcome back The Eco Committee members welcomed one another back to the Main school building. As there were routines established at the decant site that could no longer be continued the Eco committee decided to review our current situation. Recycl
UPDATES FROM BARATZ & ASSOCIATES, P. A. FOR THE HEALTHCARE INDUSTRY ASTRAZENECA PAYS $520 MILLION PLUS 5 YEARS CORPORATE The Department of Justice (DOJ) announced on April 27, as authors of articles written by AZ and its agents”. Also, 2010 that AstraZeneca LP (AZ) and AstraZenecaAZ “offered and paid illegal remuneration to doctors to Pharmaceuticals LP will pay $520 million